Literature DB >> 6089842

Low incidence of calcium pyrophosphate dihydrate crystal deposition in rheumatoid arthritis, with modification of radiographic features in coexistent disease.

M Doherty, P Dieppe, I Watt.   

Abstract

A negative correlation between rheumatoid arthritis (RA) and calcium pyrophosphate dihydrate (CPPD) crystal deposition was demonstrated in separate controlled radiographic and synovial fluid surveys of RA patients aged 55-75 years. Knee chondrocalcinosis was detected in 14% of 135 normal controls and 28% of 87 post-meniscectomy ("joint damage") controls (P less than 0.05), but only 3% of 100 RA and 75 osteoarthritis patients revealed CPPD crystals in 1% and 23%, respectively (P less than 0.01). Ten subjects with coexistent RA and CPPD deposition were also studied; 7 showed radiographic features atypical of RA, including patchy, asymmetric disease, retained bone density, prominent osteophytosis, well-corticated cysts, and paucity of progressive erosive disease. It is suggested that rheumatoid joint damage, unlike that in osteoarthritis, is not conducive to CPPD crystal formation. When RA and CPPD coexist, atypical radiographic features reflecting a hypertrophic reparative response may occur.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6089842     DOI: 10.1002/art.1780270906

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

1.  CPPD crystal deposition disease in patients with rheumatoid arthritis.

Authors:  J C Gerster; P A Varisco; J Kern; J Dudler; A K L So
Journal:  Clin Rheumatol       Date:  2005-12-20       Impact factor: 2.980

2.  Calcium Pyrophosphate Deposition Disease and Associated Medical Comorbidities: A National Cross-Sectional Study of US Veterans.

Authors:  Crystal Kleiber Balderrama; Ann K Rosenthal; Daniel Lans; Jasvinder A Singh; Christie M Bartels
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-08-08       Impact factor: 4.794

3.  Detection of crystals in synovial fluids by light microscopy: sensitivity and reliability.

Authors:  C Gordon; A Swan; P Dieppe
Journal:  Ann Rheum Dis       Date:  1989-09       Impact factor: 19.103

Review 4.  Pathophysiology of articular chondrocalcinosis--role of ANKH.

Authors:  Abhishek Abhishek; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2010-11-23       Impact factor: 20.543

5.  UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte.

Authors:  R L Neame; A J Carr; K Muir; M Doherty
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

6.  Synovial fluid pyrophosphate and nucleoside triphosphate pyrophosphatase: comparison between normal and diseased and between inflamed and non-inflamed joints.

Authors:  M Pattrick; E Hamilton; J Hornby; M Doherty
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

7.  Concurrence of rheumatoid arthritis and calcium pyrophosphate deposition disease: A case collection and review of the literature.

Authors:  Viktoriya Sabchyshyn; Irina Konon; Lawrence M Ryan; Ann K Rosenthal
Journal:  Semin Arthritis Rheum       Date:  2017-12-02       Impact factor: 5.532

8.  The detection of calcium pyrophosphate crystals in the synovial fluid of patients with rheumatoid arthritis using the cytospin technique: prevalence and clinical correlation.

Authors:  Georg Theiler; Franz Quehenberger; Franz Rainer; Manfred Neubauer; Mariana Stettin; Christoph Robier
Journal:  Rheumatol Int       Date:  2012-12-27       Impact factor: 2.631

9.  Multiple microcrystal deposition within a family.

Authors:  M Doherty; P A Dieppe
Journal:  Ann Rheum Dis       Date:  1985-08       Impact factor: 19.103

10.  The prevalence of monosodium urate and calcium pyrophosphate crystals in synovial fluid from wrist and finger joints.

Authors:  Paola Galozzi; Francesca Oliviero; Paola Frallonardo; Marta Favero; Ariela Hoxha; Anna Scanu; Mariagrazia Lorenzin; Augusta Ortolan; Leonardo Punzi; Roberta Ramonda
Journal:  Rheumatol Int       Date:  2015-10-06       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.